ProMIS Neurosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
NET LOSS PER SHARE
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	15,181,929	4,084,375
Employee Stock Option
NET LOSS PER SHARE
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	1,152,597	1,043,025
Warrants
NET LOSS PER SHARE
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	12,861,604	1,873,622
Series 1 Convertible Preferred Shares
NET LOSS PER SHARE
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive		1,166,667
Series 2 Convertible Preferred Shares
NET LOSS PER SHARE
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	1,166,667
Deferred Share Units
NET LOSS PER SHARE
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	1,061	1,061